alendronate and Asthma studies

alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.

Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).

Research Excerpts

Excerpt	Relevance	Reference
"We have recently shown that long-term use of inhaled corticosteroids decreases bone mineral density (BMD) of the lumbar spine in postmenopausal asthmatic women."	6.71	Effects of alendronate on bone mineral density and bone metabolic markers in postmenopausal asthmatic women treated with inhaled corticosteroids. ( Fujita, K; Fujita, M; Goya, K; Kasayama, S; Kawase, I; Miyatake, A; Morimoto, Y; Yamamoto, H, 2005)
" Seventy-eight participants with persistent asthma receiving 250 μg of fluticasone twice daily for 2 weeks were randomized to receive alendronate or placebo while initiating salmeterol for 8 weeks."	5.30	Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate. ( Boushey, HA; Cardet, JC; Castro, M; Chinchilli, VM; Codispoti, CD; Dyer, AM; Gerard, N; Holguin, F; Israel, E; Jiang, X; Kraft, M; Lazarus, S; Lemanske, RF; Lu, Q; Lugogo, N; Mauger, D; McIntire, K; Moore, WC; Moy, J; Ortega, VE; Peters, SP; Smith, LJ; Solway, J; Sorkness, CA; Sumino, K; Wechsler, ME; Wenzel, S, 2019)
"A 6-year-old East Indian boy with asthma was mistakenly given alendronate, a bisphosphonate, for 3 months instead of montelukast, a leukotriene-receptor antagonist."	3.72	Dispensing error leading to alendronate ingestion. ( Bailey, B; Carrière, B; Chabot, G; Lebel, D, 2003)
"We have recently shown that long-term use of inhaled corticosteroids decreases bone mineral density (BMD) of the lumbar spine in postmenopausal asthmatic women."	2.71	Effects of alendronate on bone mineral density and bone metabolic markers in postmenopausal asthmatic women treated with inhaled corticosteroids. ( Fujita, K; Fujita, M; Goya, K; Kasayama, S; Kawase, I; Miyatake, A; Morimoto, Y; Yamamoto, H, 2005)

Research

Studies (9)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Asthma Control Test (ACT)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (11.11)	18.2507
2000's	7 (77.78)	29.6817
2010's	1 (11.11)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Cardet, JC	1
Jiang, X	1
Lu, Q	1
Gerard, N	1
McIntire, K	1
Boushey, HA	1
Castro, M	1
Chinchilli, VM	1
Codispoti, CD	1
Dyer, AM	1
Holguin, F	1
Kraft, M	1
Lazarus, S	1
Lemanske, RF	1
Lugogo, N	1
Mauger, D	1
Moore, WC	1
Moy, J	1
Ortega, VE	1
Peters, SP	1
Smith, LJ	1
Solway, J	1
Sorkness, CA	1
Sumino, K	1
Wechsler, ME	1
Wenzel, S	1
Israel, E	1
Pala, G	1
Perfetti, L	1
Cappelli, I	1
Caminati, M	1
Moscato, G	1
Isik, A	1
Uras, I	1
Uyar, ME	1
Karakurt, F	1
Kaftan, O	1
Carrière, B	1
Bailey, B	1
Chabot, G	1
Lebel, D	1
Kasayama, S	1
Fujita, M	1
Goya, K	1
Yamamoto, H	1
Fujita, K	1
Morimoto, Y	1
Kawase, I	1
Miyatake, A	1
Smith, BJ	1
Laslett, LL	1
Pile, KD	1
Phillips, PJ	1
Phillipov, G	1
Evans, SM	1
Esterman, AJ	1
Berry, JG	1
Ornoy, A	1
Wajnberg, R	1
Diav-Citrin, O	1
Goldstein, MF	1
Fallon, JJ	1
Harning, R	1
Lau, EM	1
Woo, J	1
Chan, YH	1
Li, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Proof of Concept Study of Alendronate for Asthma[NCT02230332]	Phase 2/Phase 3	78 participants (Actual)	Interventional	2015-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Asthma Control Test : Score calculated as the sum total of a 5-item questionnaire. Each item ranges from 1 (poor control) to 5 (good control) so that the range of the total score is 5 to 25. Scores below 20 indicate that asthma is not well controlled. (NCT02230332)
Timeframe: 8 weeks after randomization

Beta-2 Adrenergic Receptor Agonist-induced cAMP Production

Intervention	units on a scale (Mean)
Alendronate	22.2
Placebo	22.2

Peripheral blood mononuclear cells cAMP concentrations measured using isoproterenol (ISO) as a beta-2 adrenergic receptor agonist, and using phosphate buffered saline (PBS) as a positive control. The outcome is expressed as the ratio of cAMP concentration using ISO relative to cAMP concentration using PBS. (NCT02230332)
Timeframe: 8 weeks after randomization

Fractional Exhaled Nitrix Oxide

Peripheral Blood Mononuclear Cell ADRB2 Cell Surface Density

Salivary Alpha Amylase Ratio (Post-Salmeterol / Pre-Salmeterol)

Intervention	ratio (Geometric Mean)
Alendronate	5.9
Placebo	5.9

Intervention	parts per billion (Geometric Mean)
Alendronate	16.8
Placebo	15.4

Intervention	number of receptors per cell (Geometric Mean)
Alendronate	1680
Placebo	1863

Salivary Alpha Amylase (sAA) levels from saliva samples obtained through passive drooling, before and 1 hour after Salmeterol administration. The outcome is expressed as the ratio of the Post-Salmeterol to the Pre-Salmeterol sAA levels. (NCT02230332)
Timeframe: 8 weeks after randomization

Salmeterol Protected Methacholine Challenge PC20

Intervention	ratio (Mean)
Alendronate	1.6
Placebo	1.6

Following administration of Salmeterol, the concentration of Methacholine required to produce a 20% drop in FEV1 - measured in mg/ml and reported on log base 2 scale. (NCT02230332)
Timeframe: 8 weeks after randomization

Article	Year
Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate. The Journal of allergy and clinical immunology, 2019, Volume: 144, Issue:2 Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Alendronate; Asthma; Double-Blind Method	2019
Effects of alendronate on bone mineral density and bone metabolic markers in postmenopausal asthmatic women treated with inhaled corticosteroids. Metabolism: clinical and experimental, 2005, Volume: 54, Issue:1 Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Alendronate; Asthma; Bone and Bones; Bone	2005
Randomized controlled trial of alendronate in airways disease and low bone mineral density. Chronic respiratory disease, 2004, Volume: 1, Issue:3 Topics: Absorptiometry, Photon; Aged; Alendronate; Asthma; Bone Density; Bone Density Conservation Agents; F	2004
Alendronate for the prevention of bone loss in patients on inhaled steroid therapy. Bone, 2001, Volume: 29, Issue:6 Topics: Administration, Inhalation; Alendronate; Asthma; Bone Density; Double-Blind Method; Female; Glucocor	2001

Article	Year
Occupational rhinitis to sodium alendronate. Allergy, 2008, Volume: 63, Issue:8 Topics: Adult; Alendronate; Asthma; Female; Humans; Occupational Diseases; Occupational Exposure; Rhinitis	2008
Alendronate-induced asthma. The Annals of pharmacotherapy, 2009, Volume: 43, Issue:3 Topics: Alendronate; Asthma; Bone Density Conservation Agents; Drug Hypersensitivity; Female; Humans; Middle	2009
Dispensing error leading to alendronate ingestion. The Annals of pharmacotherapy, 2003, Volume: 37, Issue:1 Topics: Acetates; Alendronate; Asthma; Calcium Channel Blockers; Child; Cyclopropanes; Drug Packaging; Esoph	2003
The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reproductive toxicology (Elmsford, N.Y.), 2006, Volume: 22, Issue:4 Topics: Adult; Alendronate; Arthritis, Psoriatic; Arthritis, Rheumatoid; Asthma; Behcet Syndrome; Berylliosi	2006

alendronate and Asthma